Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $15

Benzinga Newsdesk www.benzinga.com Positive 76.3%

Neg 0% Neu 0% Pos 76.3%

Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $13 to $15.